Oppenheimer Asset Management Inc. bought a new position in Amgen Inc. (NASDAQ:AMGN) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 37,530 shares of the medical research company’s stock, valued at approximately $6,157,000.

A number of other institutional investors have also made changes to their positions in AMGN. Swiss National Bank raised its position in shares of Amgen by 26.5% in the first quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock worth $432,490,000 after buying an additional 551,600 shares in the last quarter. Morningstar Investment Services LLC raised its position in shares of Amgen by 283.8% in the first quarter. Morningstar Investment Services LLC now owns 497,503 shares of the medical research company’s stock worth $81,625,000 after buying an additional 367,894 shares in the last quarter. Karp Capital Management Corp acquired a new position in shares of Amgen during the first quarter worth $54,888,000. Bank of Montreal Can raised its position in shares of Amgen by 10.5% in the first quarter. Bank of Montreal Can now owns 2,837,456 shares of the medical research company’s stock worth $465,543,000 after buying an additional 269,586 shares in the last quarter. Finally, State of Tennessee Treasury Department raised its position in shares of Amgen by 51.4% in the first quarter. State of Tennessee Treasury Department now owns 783,570 shares of the medical research company’s stock worth $128,560,000 after buying an additional 265,931 shares in the last quarter. Institutional investors and hedge funds own 79.53% of the company’s stock.

Amgen Inc. (NASDAQ:AMGN) traded up 0.48% during midday trading on Friday, reaching $169.93. The company’s stock had a trading volume of 414,401 shares. Amgen Inc. has a 12-month low of $133.64 and a 12-month high of $184.21. The firm has a market cap of $123.99 billion, a price-to-earnings ratio of 15.48 and a beta of 1.35. The company’s 50-day moving average is $174.60 and its 200 day moving average is $167.37.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. The company had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. Amgen’s revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.84 earnings per share. Equities analysts forecast that Amgen Inc. will post $12.57 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Thursday, August 17th will be issued a dividend of $1.15 per share. The ex-dividend date of this dividend is Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a yield of 2.72%. Amgen’s dividend payout ratio is currently 41.93%.

COPYRIGHT VIOLATION NOTICE: This piece was published by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/11/37530-shares-in-amgen-inc-nasdaqamgn-acquired-by-oppenheimer-asset-management-inc.html.

Several equities analysts have recently commented on AMGN shares. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $189.00 price objective on shares of Amgen in a research report on Friday, June 30th. Cowen and Company reiterated an “outperform” rating and set a $209.00 price objective on shares of Amgen in a research report on Wednesday, April 19th. Jefferies Group LLC reiterated a “hold” rating and set a $180.00 price objective on shares of Amgen in a research report on Monday, May 22nd. BidaskClub upgraded Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 23rd. Finally, Morgan Stanley increased their price objective on Amgen from $183.00 to $184.00 and gave the company an “overweight” rating in a research report on Tuesday, June 13th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $186.64.

In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the company’s stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the sale, the senior vice president now owns 24,214 shares in the company, valued at $3,738,641.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.20% of the stock is owned by corporate insiders.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.